Education
About Us
Working with TipRanks
Follow Us
BCAL Diagnostics Limited (AU:BDX)
ASX:BDX
BDX Stock Chart & Stats
AU$0.10
>-AU$0.01(-2.06%)
At close: 4:00 PM EST
AU$0.10
>-AU$0.01(-2.06%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.16
Previous CloseN/A
Volume98.04K
Average Volume (3M)421.90K
Market Cap
AU$42.33M
Enterprise ValueAU$46.45M
Total Cash (Recent Filing)AU$3.33M
Total Debt (Recent Filing)AU$3.78M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding368,067,630
10 Day Avg. Volume534,308
30 Day Avg. Volume421,904
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.64
Price to Sales (P/S)1047.06
P/FCF Ratio-3.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Diagnostic Product And IPBCAL Diagnostics has a narrowly focused business model developing blood-based breast cancer diagnostics and related intellectual property. A clear clinical focus and proprietary assays create durable product differentiation and an addressable medical market that supports long-term commercialization if clinical/regulatory milestones are met.
Manageable Leverage And Capital StructureThe company’s leverage is moderate, with a debt-to-equity ratio around 0.38 and a relatively high equity ratio. This balance sheet structure reduces near-term refinancing risk and provides flexibility to fund R&D or commercialization activities over the next several months without excessive fixed-charge burdens, supporting operational continuity while losses persist.
Some Free-cash-flow Coverage Of LossesDespite negative operating cash flow, the reported free cash flow to net income ratio above 1.0 indicates pockets of cash conversion that partially offset accounting losses. This suggests limited but meaningful cash generation levers exist, which can extend runway and reduce immediate financing dependence while management pursues commercialization or cost improvements.
Bears Say
Severe Revenue CollapseA near-total revenue collapse is a structural red flag: a -99.16% decline indicates loss of commercial traction or one-off revenue loss that undermines scalability. Over a 2–6 month horizon this greatly increases dependence on external funding and hampers the company’s ability to invest in clinical validation, commercial rollout, or durable growth initiatives.
Deep And Persistent LossesVery large negative margins signal that the business is destroying shareholder capital and is not covering operating costs from revenues. Persistent negative EBIT/EBITDA and a negative ROE (−116.40%) reflect structural profitability issues that will require either material commercial improvement or repeated financing to correct, weakening long-term viability until resolved.
Negative Operating Cash Flow And Shrinking FCFCore operations are consuming cash and free cash flow is declining, with a reported FCF growth rate of -14.23%. Negative operating cash flow is a durable operational weakness that constrains reinvestment in trials, regulatory activities, and commercialization, increasing the likelihood of dilution or higher-cost financing to sustain the business.
BCAL Diagnostics Limited News
BDX FAQ
What was BCAL Diagnostics Limited’s price range in the past 12 months?
BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.
What is BCAL Diagnostics Limited’s market cap?
BCAL Diagnostics Limited’s market cap is AU$42.33M.
When is BCAL Diagnostics Limited’s upcoming earnings report date?
BCAL Diagnostics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 190 days.
How were BCAL Diagnostics Limited’s earnings last quarter?
BCAL Diagnostics Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is BCAL Diagnostics Limited overvalued?
According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued.
Does BCAL Diagnostics Limited pay dividends?
BCAL Diagnostics Limited does not currently pay dividends.
What is BCAL Diagnostics Limited’s EPS estimate?
BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BCAL Diagnostics Limited have?
BCAL Diagnostics Limited has 368,067,630 shares outstanding.
What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?
BCAL Diagnostics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of BCAL Diagnostics Limited?
Currently, no hedge funds are holding shares in AU:BDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BCAL Diagnostics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BDX Sentiment 87%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$23.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.16%
12-Months-Change
Fundamentals
Return on Equity
-97.79%
Trailing 12-Months
Asset Growth
-19.21%
Trailing 12-Months
Company Description
BCAL Diagnostics Limited
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Technical Analysis
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
―
Imagion Biosystems Ltd.
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---